{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:27:22Z","timestamp":1648837642634},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1982,9,1]],"date-time":"1982-09-01T00:00:00Z","timestamp":399686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1982,9]]},"DOI":"10.1007\/bf00296753","type":"journal-article","created":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T10:44:22Z","timestamp":1097059462000},"page":"10-12","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts"],"prefix":"10.1007","volume":"9","author":[{"given":"D. R.","family":"Gandara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Ries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. B.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Koretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. Br J Haematol 33: 451","journal-title":"Br J Haematol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0014-2964(77)90088-3","volume":"13","author":"L Brandt","year":"1977","unstructured":"Brandt L, Konyves I (1977) Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia. Eur J Cancer 13: 393","journal-title":"Eur J Cancer"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00254086","volume":"2","author":"L Brandt","year":"1979","unstructured":"Brandt L, Konyves I (1979) Prednimustine in adult acute myeloid leukaemia. Cancer Chemother Pharmacol 2: 133","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.0954-6820.1975.tb04925.x","volume":"197","author":"L Brandt","year":"1975","unstructured":"Brandt L, Konyves I, Moller TR (1975) Therapeutic effect of LEO 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. Chronic lymphocytic leukemia. Acta Med Scand 197: 317","journal-title":"Acta Med Scand"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0002-9343(79)90451-0","volume":"66","author":"JR Cohen","year":"1979","unstructured":"Cohen JR, Cregar WP, Greenberg PL, Schrier SL (1979) Subacute myeloid leukemia. Am J Med 66: 959","journal-title":"Am J Med"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0014-2964(73)90071-6","volume":"9","author":"AH Evenaar","year":"1973","unstructured":"Evenaar AH, Wins EH, Van Putten LM (1973) Cell killing effectiveness of an alkylating steroid (LEO-1031). Eur J Cancer 9: 773","journal-title":"Eur J Cancer"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM197905243002105","volume":"300","author":"RP Gale","year":"1979","unstructured":"Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300: 1189","journal-title":"N Engl J Med"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(77)91366-6","volume":"1","author":"RP Gale","year":"1977","unstructured":"Gale RP, Cline MJ (1977) High remission-induction rate in acute myeloid leukaemia. Lancet 1: 497","journal-title":"Lancet"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-94-6-753","volume":"94","author":"RP Gale","year":"1981","unstructured":"Gale RP, Foon KA, Cline MJ, Zighelboim J (1981) Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 94: 753","journal-title":"Ann Intern Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-0609.1979.tb02738.x","volume":"23","author":"K Juul","year":"1979","unstructured":"Juul K, Sorenson P, Pedersen-Bjergaard J, Krogh Jensen M (1979) Phase II trial of Prednimustine, Leo-1031 (NSC-134087), in acute non-lymphocytic leukaemia. Scand J Haematol 23: 388","journal-title":"Scand J Haematol"},{"key":"CR11","first-page":"277","volume":"60","author":"JH Kaufman","year":"1976","unstructured":"Kaufman JH, Hanjura GL, Mittelman A, Aungst CW, Murphy GP (1976) Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat Rep 60: 277","journal-title":"Cancer Treat Rep"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7326\/0003-4819-93-2-347","volume":"93","author":"HP Koeffler","year":"1980","unstructured":"Koeffler HP, Golde DW (1980) Human preleukemia. Ann Intern Med 93: 347","journal-title":"Ann Intern Med"},{"key":"CR13","first-page":"98","volume":"375","author":"I Konyves","year":"1976","unstructured":"Konyves I, Liljekuist J (1976) Review on the clinical experience with Prednimustine (LEO 1030). Excerpta Medica Int Congr Series 375: 98","journal-title":"Excerpta Medica Int Congr Series"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.0954-6820.1975.tb04926.x","volume":"197","author":"TR Moller","year":"1975","unstructured":"Moller TR, Brandt L, Konyves I, Lindberg LG (1975) Therapeutic effect of LEO 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. II. Lymphocytic lymphoma. Acta Med Scand 197: 323","journal-title":"Acta Med Scand"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(19800715)46:2<253::AID-CNCR2820460205>3.0.CO;2-1","volume":"46","author":"HT Mouridsen","year":"1980","unstructured":"Mouridsen HT, Kristensen D, Nielsen JH, Dombernowsky P (1980) Phase II trial of Prednimustine, L-1031, (NSC-134087) in advanced breast cancer. Cancer 46: 253","journal-title":"Cancer"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/1097-0142(197912)44:6<1976::AID-CNCR2820440603>3.0.CO;2-#","volume":"44","author":"Y Najean","year":"1979","unstructured":"Najean Y, Pecking A (1979) Refractory anemia with excess of blast cells: Prognostic factors and effect of treatment with androgens or cytosine arabinoside. Cancer 44: 1976","journal-title":"Cancer"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0954-6820.1980.tb09708.x","volume":"207","author":"J Pedersen-Bjergaard","year":"1980","unstructured":"Pedersen-Bjergaard J, Hansen MM, Geisler CH, Nissen NI (1980) Clinical trial of Prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. Acta Med Scand 207: 215","journal-title":"Acta Med Scand"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/1097-0142(19800815)46:4<663::AID-CNCR2820460406>3.0.CO;2-9","volume":"46","author":"BA Peterson","year":"1980","unstructured":"Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Malloy M (1980) Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia. Cancer 46: 663","journal-title":"Cancer"},{"key":"CR19","first-page":"89","volume":"61","author":"HD Preisler","year":"1977","unstructured":"Preisler HD, Bjornsson S, Henderson ES (1977) Adriamycin-cytosine arabinoside therapy for adult acute myeloid leukemia. Cancer Treat Rep 61: 89","journal-title":"Cancer Treat Rep"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/1097-0142(19800601)45:11<2816::AID-CNCR2820451117>3.0.CO;2-Q","volume":"45","author":"J Reiffers","year":"1980","unstructured":"Reiffers J, Raynal F, Broustet A (1980) Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factors. Cancer 45: 2816","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00296753.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00296753\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00296753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T20:12:45Z","timestamp":1554754365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00296753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1982,9]]}},"alternative-id":["BF00296753"],"URL":"https:\/\/doi.org\/10.1007\/bf00296753","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,9]]}}}